The subsequent studies demonstrated that the PDE4 inhibitor rolipram was able to ameliorate Aβ1-42-induced learning and memory impairment by regulating the HPA axis, leading to increases in cAMP-related proteins such as the ratio of pCREB/CREB and BDNF expression. The gene discussed is BDNF; the disease is memory impairment.